Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai, 200040, China.
Department of Hepatic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
J Gastrointest Surg. 2019 May;23(5):922-932. doi: 10.1007/s11605-018-4037-x. Epub 2018 Nov 16.
In China, hepatitis B virus (HBV) is an important causative factor of hepatocellular carcinoma (HCC). The contribution and interaction of fibrosis-4 (FIB-4) score and total tumor volume (TTV) in association with HCC recurrence is unknown. A reliable point score based on the FIB-4 score, TTV, and differentiation grade was established to predict the postoperative recurrence of HBV-related HCC patients who underwent hepatic resection (HR).
Three hundred thirty-eight HBV-related HCC patients from three institutions treated by HR were enrolled in this retrospective study. Prognostic factors were also evaluated by univariate and multivariate analysis using Cox's proportional hazards model in the training cohort. The DFT score was established by a Cox regression model and validated in the internal cohort and the external cohorts from the other two institutions.
The DFT score differentiated four groups of HBV-related HCC patients (0, 1-2, 3, 4-5 points) with distinct prognosis (median recurrence-free survival (RFS), 72.7 vs. 53.0 vs. 23.2 vs. 5.7 months; P < 0.05). Its predictive accuracy as determined by the area under the receiver operating characteristic curve (AUC) at 1, 3, and 5 years (AUCs 0.7319, 0.7031, and 0.6972) was greater than the other three staging systems for HCC. These findings were supported by the validation cohorts.
The DFT model is a reliable and objective model to predict the RFS of HBV-related HCC patients after HR.
在中国,乙型肝炎病毒(HBV)是肝细胞癌(HCC)的重要致病因素。纤维化-4(FIB-4)评分和总肿瘤体积(TTV)与 HCC 复发的相关性及其相互作用尚不清楚。本研究建立了一种基于 FIB-4 评分、TTV 和分化程度的可靠评分系统,以预测接受肝切除术(HR)的 HBV 相关 HCC 患者术后复发的风险。
本回顾性研究共纳入 338 例来自三家医院的 HBV 相关 HCC 患者。在训练队列中,采用单因素和多因素 Cox 比例风险模型评估预后因素。通过 Cox 回归模型建立 DFT 评分,并在内部队列和另外两家医院的外部队列中进行验证。
DFT 评分将 HBV 相关 HCC 患者分为四组(0、1-2、3、4-5 分),具有不同的预后(中位无复发生存期(RFS)分别为 72.7、53.0、23.2 和 5.7 个月;P<0.05)。其在 1、3 和 5 年的预测准确性由受试者工作特征曲线下面积(AUC)确定(AUC 分别为 0.7319、0.7031 和 0.6972),优于其他三种 HCC 分期系统。这些发现也得到了验证队列的支持。
DFT 模型是一种可靠和客观的模型,可预测 HR 后 HBV 相关 HCC 患者的 RFS。